Cenicriviroc

TANDEM study shows potential of HistoIndex SHG/TPE imaging and AI-based technology in evaluating the effects of combination therapy for NASH

Retrieved on: 
Thursday, June 15, 2023
Photon, Steatosis, EASL, FXR, CET, NASH, Second-harmonic imaging microscopy, Research, Inflammation, Tropifexor, Congress, Fibrosis, HIV disease progression rates, Patient, Artificial intelligence, CCR5, TANDEM, Fatty liver disease, Digital, AI, Newcastle University, CCR2, SHG, Cenicriviroc, Medical imaging

The study, published recently in Hepatology , compared the effectiveness of Tropifexor plus Cenicriviroc combination therapy versus monotherapy1.

Key Points: 
  • The study, published recently in Hepatology , compared the effectiveness of Tropifexor plus Cenicriviroc combination therapy versus monotherapy1.
  • The study found that the AI-based analysis using SHG/TPE digital pathology was able to detect effects seen in different zones of the liver lobule that may not have been detected using conventional microscopy.
  • The fully quantitative co-localization and zonal assessment has the potential to provide greater details in evaluating the effects of combination therapy for NASH.
  • Tropifexor is a selective agonist of farnesoid X receptor (FXR), which regulates bile acid metabolism and inflammation.

Inventiva announces completion of patient visits for its Phase IIb clinical study with lanifibranor in NASH

Retrieved on: 
Tuesday, March 17, 2020
Health, Medicine, Medical research, Clinical research, Design of experiments, Clinical pharmacology, Clinical trial, Pharmaceutical industry, Placebo-controlled study, Non-alcoholic fatty liver disease, Tcelna, Cenicriviroc

The NATIVE (NAsh Trial to Validate IVA337 Efficacy) trial is a 24-week randomized, double-blind, placebo-controlled Phase IIb clinical study evaluating lanifibranor in the treatment of patients with non-alcoholic steatohepatitis (NASH).

Key Points: 
  • The NATIVE (NAsh Trial to Validate IVA337 Efficacy) trial is a 24-week randomized, double-blind, placebo-controlled Phase IIb clinical study evaluating lanifibranor in the treatment of patients with non-alcoholic steatohepatitis (NASH).
  • Throughout the study, the safety profile of lanifibranor has been regularly assessed by an external, independent Data Safety Monitoring Board (DSMB).
  • The NATIVE (NAsh Trial to Validate IVA337 Efficacy) clinical trial is a 24-week randomized, double-blind, placebo-controlled Phase IIb clinical trial evaluating lanifibranor in the treatment of patients with non-alcoholic steatohepatitis (NASH).
  • Inventiva is currently evaluating lanifibranor in a Phase IIb clinical trial for the treatment of this disease for which there are currently no approved therapies.